The impact of exercise on growth factors (VEGF and FGF2): results from a 12-month randomized intervention trial

Table 1 Intention-to-treat and per-protocol analysis of FGF2 and VEGF concentrations between high and moderate volume exercise groups in BETA (n = 386)

Group	n	Baseline		6 Months		12 Months		Treatment Effect		Between-Group P ^c
Group	n	Geo-metric Mean ^a	95% CI	Geo-metric Mean	95% CI	Geo-metric Mean	95% CI	Ratio of High/Moderate ^b	95% CI	Between-Group P ^c
Intention-to-treat
FGF2
High	195	121.3	114.4–128.5	116.1	110.1–122.4	123.3	117.7–129.2	0.98	0.94–1.02	0.28
Moderate	191	118.8	111.9–126.2	122.9	116.2–130.0	120.1	113.1–127.6
VEGF
High	195	62.3	55.1–70.4	58.5	51.7–66.3	58.6	51.3–66.9	0.94	0.86–1.02	0.15
Moderate	191	64.9	57.2–73.6	63.6	55.7–72.6	67.3	58.9–76.9
Per-protocol ^d
FGF2										0.64
High	80	119.8	110.8–129.4	116.0	107.3–125.3	121.2	113.5–129.4	1.02	0.95–1.10
Moderate	58	112.6	100.0–126.7	113.9	101.9–127.3	109.6	98.3–122.2
VEGF										0.74
High	80	60.6	50.8–72.3	60.6	50.0–73.4	58.0	47.6–70.7	0.98	0.84–1.13
Moderate	58	70.3	54.2–91.0	64.9	49.9–84.6	74.0	56.9–96.3

a. Geometric mean of FGF2 and VEGF was in the unit of pg/mL
b. The geometric mean ratios were estimated from least square means for the difference in treatment effect between high and moderate volume exercisers averaged across the entire study period adjusted for the baseline values and then back log-transformed
c. P value corresponds to the null hypothesis that the ratio of treatment effect between high- and moderate-volume groups equals 1 against the 2-sided alternative hypothesis
d. Women assigned to the moderate-volume group were adherent if they completed 90 to 100% of the exercise prescription (mean, 135–150 min/wk), weeks 13 to 52 at full prescription; women assigned to the high-volume group were adherent if they completed at least 90% of the exercise prescription (mean, ≥270 min/wk), weeks 13 to 52 at full prescription

ISSN: 1861-6909